Authors: Alice Greenway, Future Science Group
Cidara Therapeutics, Inc. (CA, USA) recently reported positive topline results from the international, multicenter, double-blind Phase II STRIVE clinical trial of its lead antifungal candidate rezafungin acetate.
Rezafungin is a novel antifungal echinocandin that has been developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections such as Candida.
To view restricted content, please:
